Skip to content
    LFMD
    Earnings call· Jun 2026(Q2 FY26)

    LifeMD Q2 FY26 earnings call LFMD

    Aug 5, 2026 Source

    Executive summary

    LifeMD, Inc. Q2 FY26 — Strategic Shift Towards Quality Revenue and Diversified Growth

    LifeMD's Q2 FY26 results reflect a strategic pivot towards quality revenue and diversified patient acquisition channels, moving beyond a reliance on paid media. While this transition led to a near-term adjusted EBITDA miss and a revised full-year outlook, the company reported strong underlying improvements in recurring revenue mix, gross margin, and operating costs. Management is focused on building longer-term patient relationships through branded therapies, pharmacy expansion, and strategic partnerships, aiming for a return to adjusted EBITDA profitability in Q3.

    Highlights

    5

    • Recurring rebill revenue represented approximately 84% of total revenue.

    • Gross margin expanded to approximately 89%, an improvement of approximately 60 basis points sequentially.

    • Advertising and marketing expense declined by approximately $1.8 million sequentially.

    • Other general and administrative expenses declined approximately $1.5 million sequentially.

    • Women's health patient base grew 134% quarter over quarter.

    Concerns

    5

    • Adjusted EBITDA was a loss of approximately $3.5 million, missing internal targets.

    • Revenue was $47.3 million, within guidance but down approximately 6% sequentially and 4% year-over-year.

    • Elevated customer acquisition costs (CAC) early in the quarter due to competitive market for GLP-1s.

    • Lower upfront revenue associated with the new $39 introductory GLP-1 pricing.

    • Full-year 2026 adjusted EBITDA outlook revised to negative $6 million to break even, down from prior expectations.

    Guidance & targets

    13
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $205.5 million to $212.5 million
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    negative $6 million to break even
    high materiality
    High
    Q3 FY26 Revenue
    $48 million to $51 million
    medium materiality
    High
    Q3 FY26 Adjusted EBITDA
    negative $1 million to positive $2 million
    medium materiality
    High
    Q4 FY26 Revenue
    $60 million to $64 million
    medium materiality
    High
    Q4 FY26 Adjusted EBITDA
    $3 million to $6 million
    medium materiality
    High
    Q4 FY26 Annualized Revenue Run Rate
    approximately $250 million
    high materiality
    High
    Q4 FY26 Annualized Adjusted EBITDA Run Rate
    approximately $22 million
    high materiality
    High
    Zyosted Launch Investment
    $2 million to $3 million
    medium materiality
    High
    Zyosted EBITDA Accretion
    accretive to LifeMD's EBITDA
    medium materiality
    Medium
    Women's Health Patient Base Growth
    another 300% to 400%
    medium materiality
    High
    Compounded Products Launch
    more than 30 compounded products
    low materiality
    High
    Women's Health Quarterly Revenue Run Rate
    between $3 million and $5 million
    medium materiality
    Medium

    Operational metrics

    18
    Revenue
    $47.3 milliondown approximately 6% sequentially, down approximately 4% YoY
    Q2 FY26

    Within guidance range of $47 million to $50 million. Reflects planned step-down in marketing investments, increased CPA levels, and impact of weight management price change.

    Adjusted EBITDA
    negative $3.5 millionmissed target
    Q2 FY26

    Reflecting elevated customer acquisition costs and new $39 introductory GLP-1 pricing. Monthly trajectory improved consistently through the quarter.

    Recurring rebill revenue mix
    84%
    Q2 FY26

    Represents the installed base as the economic engine, generating high contribution margin revenue.

    Gross margin
    89%up approximately 60 bps sequentially
    Q2 FY26

    Gross profit was essentially flat despite lower year-over-year revenue, demonstrating improving business composition and economics.

    Advertising and marketing expense
    $28 milliondeclined $1.8 million sequentially
    Q2 FY26

    Slightly above the range indicated on prior call, but reflects planned step-down.

    General and administrative expenses
    declined approximately $1.5 millionsequentially
    Q2 FY26

    Reductions began to show progressively during the quarter, expected to be more visible in H2.

    Other operating expenses
    declined approximately $700,000sequentially
    Q2 FY26

    Part of overall expense actions.

    Weight management CAC reduction
    approximately 50% lowervs. peak in June
    since mid-June

    Result of strategic shift away from sole reliance on paid media.

    Weight management multi-month package selection
    approximately 85%vs. 25% prior
    following pricing change

    Lowering introductory price to $39 materially improved program attraction and patient composition, leading to stronger retention and higher lifetime value.

    Weight management patients
    108,000
    Q2 FY26 end

    Reflects the highly competitive market for branded GLP-1 care.

    Women's health patient base growth
    134%quarter over quarter
    Q2 FY26

    Despite some pressure during the quarter, recent operating trends improved meaningfully.

    New patient acquisitions (Women's Health)
    50 to 100
    recent weeks

    Over the last week or two, with several days in this range, indicating strong growth with strong unit economics.

    New providers hired
    47
    Q2 FY26

    Hired to support anticipated demand across programs in H2 FY26.

    Pharmacy gross margins
    approximately 90%
    Q2 FY26

    Continued in-house fulfillment was an important contributor to overall gross margin expansion.

    Covered lives
    approximately 175 million
    Q2 FY26

    Infrastructure now reaches this many covered lives, improving affordability and retention for patients.

    Insurance penetration
    approximately 10%
    Q2 FY26

    Still in early stages of bringing full range of specialty programs onto this infrastructure.

    GAAP net loss from continuing operations attributable to common stockholders
    $7.9 million
    Q2 FY26

    Equivalent to $0.16 per share.

    Cash balance
    $25.1 million
    Q2 FY26 end

    Cash flow pressured by marketing investment and timing effects of $39 introductory offer transition.

    Industry KPIs

    6
    MetricValueDetails
    Free cash flowpressured by ongoing marketing investment and timing effects of the transition to the $39 introductory offer
    Adjusted EBITDAnegative $3.5 millionUSD
    Net revenue retentionabove 80%%
    Healthcare client count356,000subscribers
    Revenue adjusted EBITDA guidanceFY26 Revenue: $205.5 million to $212.5 million; FY26 Adjusted EBITDA: negative $6 million to break evenUSD
    Subscription recurring revenue growth84%%

    Product announcements

    1
    ProductTypeDetails
    Compounded Productslaunch

    Deals & partnerships

    1
    Halazime's wholly-owned subsidiary, Anteros PharmaExclusive telehealth co-marketing collaboration for Zyosted, an FDA-approved, once-weekly, subcutaneous testosterone autoinjector.

    Initial self-pay program launched in July across 37 states at $249 per month, with affiliated pharmacies as primary dispensing. Expect insurance access to become important. Direct costs split between the two companies.

    Risks & headwinds

    5
    Elevated customer acquisition costsEarly Q2 FY26

    Elevated early in Q2, particularly for branded GLP-1 care; contributed to adjusted EBITDA shortfall.

    Mitigation: Restructured customer acquisition model, shifting mix away from sole reliance on paid media to alternative channels (pharmaceutical manufacturers, employers, insurers, Medicare, referrals). CAC for weight management down 50% since mid-June.

    Competitive pricing in weight managementEarly Q2 FY26

    Affected conversion and made LifeMD's offering less competitive at the top of the funnel.

    Mitigation: LifeMD responded by lowering introductory price of branded GLP-1 program to $39, which reduced upfront cash collection but materially improved program attraction and increased multi-month package selection from 25% to 85%.

    Near-term profitability pressure from strategic changesQ2 FY26 and H2 FY26

    Adjusted EBITDA loss of approximately $3.5 million; full-year adjusted EBITDA outlook revised to negative $6 million to break even.

    Mitigation: Expense actions (advertising/marketing down $1.8M sequentially, G&A down $1.5M sequentially) expected to become more visible in H2. Focus on executing against outlook for return to adjusted EBITDA profitability in Q3 and substantial sequential improvement in Q4.

    Compounding business shrinking faster than expectedThroughout FY26

    Very few new patients getting prescriptions for personalized compounds (other 5% of new patients, 95% on branded therapy); patients previously on compounds switched to branded therapies faster.

    Mitigation: Company views compounding as insignificant to future earnings and is focusing on branded therapies and pharmacy expansion.

    Startup investment required for Zyosted collaboration2026 and early 2027

    Anticipated $2 million to $3 million investment in 2026.

    Mitigation: Investment is contemplated in the revised outlook; initial cohorts expected to become accretive to EBITDA in mid-2027.

    What to watch in Q3 FY26

    5

    Adjusted EBITDA Profitability

    Q3 FY26
    CurrentNegative $3.5 million (Q2 FY26)
    TargetNegative $1 million to positive $2 million (Q3 FY26)

    Why it matters

    Management expects a return to adjusted EBITDA profitability in Q3, which is critical for validating the strategic shift and expense management efforts.

    We expect a return to adjusted EBITDA profitability in the third quarter and deliver substantial sequential improvement in the fourth quarter.

    Q&A highlights

    6

    What is the potential revenue opportunity for peptides if FDA permits compounding, and what is LifeMD's approach?

    Justin Schreiber stated that while there's no specific revenue number, there would be considerable demand from current patients across weight loss, hormones, and sexual health, as well as outside the platform. LifeMD plans a conservative approach, ensuring safety and proper prescription, and is working on sterile compounding capabilities or vendor partnerships.

    “if FDA follows through as they're expected to and permits some of them to be made in compounding pharmacies... it would be a pretty significant market opportunity for LifeMD.”

    asked by David Larson · answered by Justin Schreiber

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Shift in Patient Acquisition

    LifeMD is deliberately moving away from a sole reliance on paid media due to volatile auction pricing and shallow patient relationships. The company is diversifying demand channels to include pharmaceutical manufacturers (e.g., Zyosted collaboration), employers, insurers, Medicare, and patient referrals, aiming for more diversified, less volatile, and more valuable growth. Early results show acquisition costs for weight management down 50% from peak in June.

    02

    Evolution of Weight Management Business

    The company is building its weight management business around branded, FDA-approved GLP-1 therapies and longitudinal clinical care, including insurance access and manufacturer relationships. A recent pricing change to $39 for the introductory GLP-1 program, while impacting upfront cash, has significantly increased the selection of multi-month packages from 25% to 85%, leading to higher retention and lifetime value.

    03

    Growth in Women's Health

    The women's health program, designed for longitudinal, evidence-based care, saw its patient base grow 134% quarter over quarter and is expected to grow another 300-400% by year-end. This program integrates hormone therapy, sexual wellness, weight loss, and in-home labs, with plans for a bone health program, demonstrating the company's focus on deep patient relationships and cross-care offerings.

    04

    Pharmacy Expansion and Capabilities

    LifeMD's 50-State Pharmacy is becoming a strategic asset, contributing to gross margin expansion with operations carrying approximately 90% gross margins. The pharmacy is scaling across branded direct-to-patient fulfillment (e.g., Zyosted), generic medications, and personalized compounding therapies. The company plans to launch over 30 compounded products by year-end across various health categories.

    05

    Investment in Affiliated Medical Group and Technology

    The company is strengthening its affiliated medical group by hiring 47 new providers and cross-training them across men's and women's health offerings to support anticipated demand. Technology investments, particularly in AI, are embedded across the platform to improve intake, clinical decision support, patient messaging, and back-office workflows, aiming to reduce cost per patient and cost per consult.

    06

    Insurance and Strategic Partnerships

    LifeMD's benefits infrastructure now reaches approximately 175 million covered lives, with insurance penetration at about 10% for new primary care patients. The company is also advancing national strategic and employer partnerships to increase brand awareness and patient volume at attractive economics, reducing dependence on media-based acquisition.

    AI-generated summary of the company’s earnings call. Not investment advice.